^
Association details:
| Biomarker: | DLL3 expression |
|---|---|
| Cancer: | Merkel Cell Carcinoma |
| Drug: | Rova-T (rovalpituzumab tesirine) (DNA replication inhibitor, DLL3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma
Published date:
05/14/2020
Excerpt:
A 67‐year‐old patient with metastatic Merkel cell carcinoma...was enrolled into an open‐label study of Rova‐T in subjects with DLL3‐expressing advanced solid tumors...This patient received three doses of Rova‐T at 0.2 mg/kg. This patient's target lesions decreased 57% after the first two cycles of Rova‐T, consistent with radiographic partial response...
DOI:
10.1634/theoncologist.2019-0877
